Treatment of Macular Oedema in Patients With Hereditary Retinal Dystrophies by Applying the Micropulsed Subthreshold Laser

What this Trial Is About

Researchers are evaluating the use of subthreshold micropulsed laser treatment to reduce macular edema in patients with inherited retinal dystrophies, a group of rare eye diseases that cause progressive vision loss. Macular edema can worsen vision in these patients, and current treatments like diuretics and injections have limitations and potential side effects. This study seeks to determine if micropulsed laser therapy, which uses low energy to avoid retinal damage, can help resolve this condition. The treatment uses a specific micropulsed laser device with defined power, pulse duration, and spot size settings. Patients receive laser treatment on the first visit, with possible repeat treatments between 3 and 12 months based on response. This prospective, open-label study enrolls patients who have persistent macular edema despite prior treatments such as diuretics or anti-VEGF injections. Participants will be followed for up to 24 months with scheduled visits at 1, 3, 6, 9, 12, 18, and 24 months after treatment. At these visits, comprehensive eye exams will be performed including OCT imaging, electroretinograms, and retinography. Researchers will measure changes in central retinal thickness and assess visual acuity, retinal function, and blood flow to evaluate treatment effects and safety over time.

Micropulsed Laser in Patients With Macular Oedema in Retinal Dystrophies